VIable

NDHI
NAT IONAL DIALOGUE FOR
Healthcare Innovation
Improving Surgical Outcomes
with Immunonutrition
Organization Overview
• Nestlé Health Science is engaged in advancing the
therapeutic role of nutrition in health management
• The company operates in around 40 countries with
around 3,000 employees
• Nestlé Health Science plays a key role in the Nestlé
Group, in its quest to expand the boundaries of
nutrition, health, and wellness
Background
Surgical complications create suboptimal healthcare
outcomes by increasing hospital
readmission risks for patients and
contributing billions of dollars in
avoidable healthcare costs each
year:
• The risk of 30-day readmission
after general surgery
increases 4 times when a
complication occurs, and
one of the most common
complications is surgical site
infection 1
• One in four colon resection
patients are readmitted to the
hospital within 90 days 2
• Soft tissue surgical site infections alone contribute
$1.6 billion in direct costs annually 3
1
Kassin et al. Risk factors for 30-day hospital readmission among
general surgery patients. J Am Coll Surg 2012;215:322-330.
2
Wick EC et al. Readmission rates and cost following colorectal
surgery. Dis Colon Rectum 2011;54(12):1475-9.
3
deLissovoy G et al. Surgical site infection: incidence and impact
on hospital utilization and treatment costs. Am J Infect Control
2009;37:387-397.
To combat these avoidable outcomes, Nestlé Health
Science focuses on developing innovative therapeutic
nutrition products that meet the unique nutritional
demands that major surgery places on the body to
help reduce the risk of post-surgical complications.
Product Details
• Nestlé Health Science has developed the IMPACT ®
family of formulas to provide therapeutic nutrition
to surgery patients, through a unique combination
of immunonutrients, including arginine, omega-3
fatty acids and dietary nucleotides, that support
immune response 4
• The products are available in oral and tube-fed forms
• Positive clinical outcomes associated with IMPACT ®
products have been demonstrated in over 40
publications across many types of surgeries,
including GI cancer, head and neck cancer,
cardiothoracic, bladder cancer, orthopedic, and
gynecological cancer 5,6,7
4
Braga M et al. Immunonutrition: from laboratory to clinical practice.
Nutr 2007;23:368-370.
5
Drover JW et al. Perioperative use of arginine-supplemented
diets: a systematic review of the evidence. J Am College Surgeons
Mar 2011: 212(3): 385-399.
6
Alito Aprelino M and de Aguilar-Nascimento JE. Multimodal
Perioperative Care plus Immunonutrition versus Traditional Care
in Total Hip Arthroplasty: A Randomized Pilot Study. Nutrition
Journal 2016;15:1-7.
7
Bertrand J et al. Impact of Preoperative Immunonutrition on Morbidity
following Cystectomy for Bladder Cancer: A Case-Control
Pilot Study. World J Urol 2014;32:233-237.
An Initiative of the
83 | Improving Surgical Outcomes with Immunonutrition